Yoninah Cramer

613 total citations
17 papers, 345 citations indexed

About

Yoninah Cramer is a scholar working on Infectious Diseases, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Yoninah Cramer has authored 17 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 7 papers in Epidemiology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Yoninah Cramer's work include HIV/AIDS drug development and treatment (11 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Tuberculosis Research and Epidemiology (5 papers). Yoninah Cramer is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Tuberculosis Research and Epidemiology (5 papers). Yoninah Cramer collaborates with scholars based in United States, South Africa and Zimbabwe. Yoninah Cramer's co-authors include Susan L. Rosenkranz, Jeong-Gun Park, Kelly E. Dooley, Francesca Aweeka, David W. Haas, Susan L. Koletar, Charles R. Rinaldo, Sharon M. Wahl, David M. Asmuth and Ellen S. Chan and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Yoninah Cramer

15 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoninah Cramer United States 9 211 130 98 81 44 17 345
Neesha Rockwood United Kingdom 12 281 1.3× 160 1.2× 25 0.3× 36 0.4× 44 1.0× 24 406
Vidar Ormaasen Norway 15 273 1.3× 94 0.7× 175 1.8× 20 0.2× 31 0.7× 27 427
Wbeimar Aguilar-Jiménez Colombia 13 162 0.8× 82 0.6× 152 1.6× 100 1.2× 51 1.2× 36 405
Andrew Scourfield United Kingdom 12 217 1.0× 138 1.1× 96 1.0× 13 0.2× 20 0.5× 24 359
Catherine Knupp United States 7 320 1.5× 170 1.3× 232 2.4× 16 0.2× 51 1.2× 9 471
Edwin Thorpe United States 8 159 0.8× 77 0.6× 44 0.4× 20 0.2× 11 0.3× 10 343
Kimberly Bergman United States 9 85 0.4× 117 0.9× 88 0.9× 23 0.3× 109 2.5× 17 361
Gong Shen United States 11 349 1.7× 167 1.3× 113 1.2× 25 0.3× 86 2.0× 21 516
Jonathan Uy United States 10 280 1.3× 60 0.5× 222 2.3× 176 2.2× 42 1.0× 24 532
A. I. M. Hoepelman Netherlands 12 108 0.5× 172 1.3× 64 0.7× 20 0.2× 18 0.4× 21 349

Countries citing papers authored by Yoninah Cramer

Since Specialization
Citations

This map shows the geographic impact of Yoninah Cramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoninah Cramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoninah Cramer more than expected).

Fields of papers citing papers by Yoninah Cramer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoninah Cramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoninah Cramer. The network helps show where Yoninah Cramer may publish in the future.

Co-authorship network of co-authors of Yoninah Cramer

This figure shows the co-authorship network connecting the top 25 collaborators of Yoninah Cramer. A scholar is included among the top collaborators of Yoninah Cramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoninah Cramer. Yoninah Cramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Luetkemeyer, Anne F., Marjorie Z. Imperial, Rodney Dawson, et al.. (2025). Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis. Pharmacogenetics and Genomics. 35(4). 140–144.
2.
Podany, Anthony T., Yoninah Cramer, Marjorie Z. Imperial, et al.. (2024). Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention. Clinical Infectious Diseases. 79(4). 983–989. 2 indexed citations
3.
Karlsson, Mats O., Susan L. Rosenkranz, Yoninah Cramer, et al.. (2022). Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens. Clinical Pharmacology & Therapeutics. 112(4). 873–881. 14 indexed citations
4.
Haas, David W., Yoninah Cramer, Catherine Godfrey, et al.. (2020). Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. Pharmacogenetics and Genomics. 30(3). 45–53. 8 indexed citations
5.
Mngqibisa, Rosie, Michelle A. Kendall, Kelly E. Dooley, et al.. (2019). Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clinical Infectious Diseases. 71(3). 517–524. 7 indexed citations
6.
7.
Weinberg, Adriana, Jeong-Gun Park, Ronald J. Bosch, et al.. (2015). Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. JAIDS Journal of Acquired Immune Deficiency Syndromes. 71(2). 137–145. 5 indexed citations
8.
9.
Dooley, Kelly E., Radojka M. Savić, Jeong‐Gun Park, et al.. (2015). Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 59(6). 3399–3405. 13 indexed citations
10.
Dooley, Kelly E., Anne F. Luetkemeyer, Jeong‐Gun Park, et al.. (2014). Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin. Antimicrobial Agents and Chemotherapy. 58(9). 5245–5252. 41 indexed citations
11.
Dooley, Kelly E., Jeong-Gun Park, Susan Swindells, et al.. (2011). Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes. 59(5). 455–462. 62 indexed citations
12.
Currier, Judith S., et al.. (2011). Sex Differences in Lopinavir and Ritonavir Pharmacokinetics Among HIV-Infected Women and Men. The Journal of Clinical Pharmacology. 51(12). 1665–1673. 27 indexed citations
13.
Asmuth, David M., Robert L. Murphy, Susan L. Rosenkranz, et al.. (2010). Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial. The Journal of Infectious Diseases. 201(11). 1686–1696. 96 indexed citations
14.
Gupta, Samir K., Susan L. Rosenkranz, Yoninah Cramer, et al.. (2008). The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS. 22(15). 1919–1927. 26 indexed citations
15.
Bakshi, Rahul P., Fayez M. Hamzeh, Ian Frank, et al.. (2007). Effect of Hydroxyurea and Dideoxyinosine on Intracellular 3′-Deoxyadenosine-5′-triphosphate Concentrations in HIV-Infected Patients. AIDS Research and Human Retroviruses. 23(11). 1360–1365. 4 indexed citations
16.
Stauffer, Edouard, et al.. (1989). [Glutamic acid group poisoning. So-called Chinese restaurant syndrome].. PubMed. 47. 69–71.
17.
Cramer, Yoninah, et al.. (1987). [Relevance of individual parameters in the calculation of blood alcohol levels in relation to the volume of intake].. PubMed. 24(3). 192–8. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neesha Rockwood Breakdown of academic impact, for papers by Vidar Ormaasen Breakdown of academic impact, for papers by Wbeimar Aguilar-Jiménez Breakdown of academic impact, for papers by Andrew Scourfield Breakdown of academic impact, for papers by Catherine Knupp Breakdown of academic impact, for papers by Edwin Thorpe Breakdown of academic impact, for papers by Kimberly Bergman Breakdown of academic impact, for papers by Gong Shen Breakdown of academic impact, for papers by Jonathan Uy Breakdown of academic impact, for papers by A. I. M. Hoepelman
Rankless by CCL
2026